The impact of inflammation and cytokine expression of PM2.5 in AML

Chen,Tingting; Zhang,Juan; Zeng,Hui; Zhang,Yue; Zhang,Yong; Zhou,Xiaohuan; Zhao,Dong; Feng,Yingmei; Zhou,Hebing

doi:10.3892/ol.2018.8965

The impact of inflammation and cytokine expression of PM2.5 in AML

Authors:
- Tingting Chen
- Juan Zhang
- Hui Zeng
- Yue Zhang
- Yong Zhang
- Xiaohuan Zhou
- Dong Zhao
- Yingmei Feng
- Hebing Zhou
View Affiliations

Affiliations: Department of Hematology, Beijing Luhe Hospital, Capital Medical University, Beijing 101100, P.R. China, Department of Endocrinology, Beijing Luhe Hospital, Capital Medical University, Beijing 101100, P.R. China
Published online on: June 13, 2018 https://doi.org/10.3892/ol.2018.8965
Pages: 2732-2740

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Environmental and health issues have become a major focus of research worldwide in recent years. Particulate matter with diameter ≤2.5 µm (PM2.5) is a common air pollutant that has been demonstrated to be associated with various diseases, including acute myeloid leukemia (AML). In the present study, the effects of PM2.5 on the proliferation and inflammation were assessed using three human acute myeloid cell lines (U937, HL‑60 and KG‑1a) in vitro. Additionally, the levels of several cytokines [interleukin (IL)‑2, IL‑10, IL‑17A and tumor necrosis factor (TNF)α] in AML cells and Sprague Dawley rats were evaluated to investigate the effects of PM2.5 on cytokine expression in AML. The results revealed that PM2.5 was capable of enhancing inflammatory responses in AML cells, and increasing IL‑2, IL‑10, IL‑17A and TNFα mRNA expression in AML cells to different degrees. Furthermore, PM2.5 increased IL‑2 and IL‑10 contents in rats following 12 weeks of exposure. These results suggested that PM2.5 may serve a role in promoting the occurrence and progression of leukemia by affecting cytokine expression, and that there may be various mechanisms active in different AML subtypes.

View Figures

View References

1	Henriquez G and Urrea C: Association between air pollution and emergency consultations for respiratory diseases. Rev Med Chil. 145:1371–1377. 2017.(In Spanish). PubMed/NCBI
2	Rabiei K, Hosseini SM, Sadeghi E, Jafari-Koshki T, Rahimi M, Shishehforoush M, Lahijanzadeh A, Sadeghian B, Moazam E, Mohebi MB, et al: Air pollution and cardiovascular and respiratory disease: Rationale and methodology of CAPACITY study. ARYA Atheroscler. 13:264–273. 2017.PubMed/NCBI
3	Trnjar K, Pintarić S, Mornar Jelavić M, Nesek V, Ostojić J, Pleština S, Šikić A and Pintarić H: Correlation between occurrence and deterioration of respiratory diseases and air pollution within the legally permissible limits. Acta Clin Croat. 56:210–217. 2017. View Article : Google Scholar : PubMed/NCBI
4	Faridi S, Shamsipour M, Krzyzanowski M, Künzli N, Amini H, Azimi F, Malkawi M, Momeniha F, Gholampour A, Hassanvand MS and Naddafi K: Long-term trends and health impact of PM2.5 and O3 in Tehran, Iran, 2006–2015. Environ Int. 114:37–49. 2018. View Article : Google Scholar : PubMed/NCBI
5	Kolpakova AF, Sharipov RN and Kolpakov FA: Air pollution by particulate matter as the risk factor for the cardiovascular diseases. Gig Sanit. 96:133–137. 2017.PubMed/NCBI
6	Stachyra K, Kiepura A and Olszanecki R: Air pollution and atherosclerosis-a brief review of mechanistic links between atherogenesis and biological actions of inorganic part of particulate matter. Folia Med Cracov. 57:37–46. 2017.PubMed/NCBI
7	Hüls A, Vierkötter A, Sugiri D, Abramson MJ, Ranft U, Krämer U and Schikowski T: The role of air pollution and lung function in cognitive impairment. Eur Respir J. 51:17019632018. View Article : Google Scholar : PubMed/NCBI
8	Kim H, Kim J, Kim S, Kang SH, Kim HJ, Kim H, Heo J, Yi SM, Kim K, Youn TJ and Chae IH: Cardiovascular effects of long-term exposure to air pollution: A population-based study with 900 845 person-years of follow-up. J Am Heart Assoc. 6:e0071702017. View Article : Google Scholar : PubMed/NCBI
9	Brunekreef B and Holgate ST: Air pollution and health. Lancet. 360:1233–1242. 2002. View Article : Google Scholar : PubMed/NCBI
10	Li R, Kou X, Geng H, Xie J, Tian J, Cai Z and Dong C: Mitochondrial damage: An important mechanism of ambient PM2.5 exposure-induced acute heart injury in rats. J Hazard Mater. 287:392–401. 2015. View Article : Google Scholar : PubMed/NCBI
11	Wang C, Tu Y, Yu Z and Lu R: PM2.5 and cardiovascular diseases in the elderly: An overview. Int J Environ Res Public Health. 12:8187–8197. 2015. View Article : Google Scholar : PubMed/NCBI
12	Dabass A, Talbott EO, Venkat A, Rager J, Marsh GM, Sharma RK and Holguin F: Association of exposure to particulate matter (PM2.5) air pollution and biomarkers of cardiovascular disease risk in adult NHANES participants (2001–2008). Int J Hyg Environ Health. 219:301–310. 2016. View Article : Google Scholar : PubMed/NCBI
13	Yang A, Janssen NA, Brunekreef B, Cassee FR, Hoek G and Gehring U: Children's respiratory health and oxidative potential of PM2.5: The PIAMA birth cohort study. Occup Environ Med. 73:154–160. 2016. View Article : Google Scholar : PubMed/NCBI
14	Brosselin P, Rudant J, Orsi L, Leverger G, Baruchel A, Bertrand Y, Nelken B, Robert A, Michel G, Margueritte G, et al: Acute childhood leukaemia and residence next to petrol stations and automotive repair garages: The ESCALE study (SFCE). Occup Environ Med. 66:598–606. 2009. View Article : Google Scholar : PubMed/NCBI
15	Steffen C, Auclerc MF, Auvrignon A, Baruchel A, Kebaili K, Lambilliotte A, Leverger G, Sommelet D, Vilmer E, Hémon D and Clavel J: Acute childhood leukaemia and environmental exposure to potential sources of benzene and other hydrocarbons; a case-control study. Occup Environ Med. 61:773–778. 2004. View Article : Google Scholar : PubMed/NCBI
16	Raaschou-Nielsen O, Ketzel M, Poulsen Harbo A and Sørensen M: Traffic-related air pollution and risk for leukaemia of an adult population. Int J Cancer. 138:1111–1117. 2016. View Article : Google Scholar : PubMed/NCBI
17	Chiarini F, Lonetti A, Evangelisti C, Buontempo F, Orsini E, Evangelisti C, Cappellini A, Neri LM, McCubrey JA and Martelli AM: Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. Biochim Biophys Acta. 1863:449–463. 2016. View Article : Google Scholar : PubMed/NCBI
18	Kumar B, Garcia M, Murakami JL and Chen CC: Exosome-mediated microenvironment dysregulation in leukemia. Biochim Biophys Acta. 1863:464–470. 2016. View Article : Google Scholar : PubMed/NCBI
19	Jin XT, Chen ML, Li RJ, An Q, Song L, Zhao Y, Xiao H, Cheng L and Li ZY: Progression and inflammation of human myeloid leukemia induced by ambient PM2.5 exposure. Arch Toxicol. 90:1929–1938. 2016. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Castro-Jimenez MÁ and Orozco-Vargas LC: Parental exposure to carcinogens and risk for childhood acute lymphoblastic leukemia, Colombia, 2000–2005. Prev Chronic Dis. 8:A1062011.PubMed/NCBI
22	McHale CM, Zhang L and Smith MT: Current understanding of the mechanism of benzene-induced leukemia in humans: Implications for risk assessment. Carcinogenesis. 33:240–252. 2012. View Article : Google Scholar : PubMed/NCBI
23	Filippini T, Heck JE, Malagoli C, Del Giovane C and Vinceti M: A review and meta-analysis of outdoor air pollution and risk of childhood leukemia. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 33:36–66. 2015. View Article : Google Scholar : PubMed/NCBI
24	Sharma A, Rajappa M, Satyam A and Sharma M: Cytokines (TH1 and TH2) in patients with advanced cervical cancer undergoing neoadjuvant chemoradiation: Correlation with treatment response. Int J Gynecol Cancer. 19:1269–1275. 2009. View Article : Google Scholar : PubMed/NCBI
25	Becker Y: Molecular immunological approaches to biotherapy of human cancers-a review, hypothesis and implications. Anticancer Res. 26:1113–1134. 2006.PubMed/NCBI
26	Min G: Interleukin-2 and its application in the treatment of patients with acute myelogenous leukemia. J Leukemia Lymphoma. 17:152–155. 2008.(In Chinese).
27	Shouval DS, Ouahed J, Biswas A, Goettel JA, Horwitz BH, Klein C, Muise AM and Snapper SB: Interleukin 10 receptor signaling: Master regulator of intestinal mucosal homeostasis in mice and humans. Adv Immunol. 122:177–210. 2014. View Article : Google Scholar : PubMed/NCBI
28	Qing Yang ZL: Interleukin family cytokines and stem cell mobilization. Chin J Comp Med. 21:62–65. 2011.(In Chinese).
29	Lobo-Silva D, Carriche GM, Castro AG, Roque S and Saraiva M: Balancing the immune response in the brain: IL-10 and its regulation. J Neuroinflammation. 13:2972016. View Article : Google Scholar : PubMed/NCBI
30	de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H and de Vries JE: Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 174:915–924. 1991. View Article : Google Scholar : PubMed/NCBI
31	Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, Blaisdell S, Basham B, Dai J, Grein J, et al: IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell. 20:781–796. 2011. View Article : Google Scholar : PubMed/NCBI
32	Wang Y, Ma Y, Fang Y, Wu S, Liu L, Fu D and Shen X: Regulatory T cell: A protection for tumour cells. J Cell Mol Med. 16:425–436. 2012. View Article : Google Scholar : PubMed/NCBI
33	Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, Núñez G and Zou W: Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res. 72:420–429. 2012. View Article : Google Scholar : PubMed/NCBI
34	Mocellin S, Marincola F, Rossi CR, Nitti D and Lise M: The multifaceted relationship between IL-10 and adaptive immunity: Putting together the pieces of a puzzle. Cytokine Growth Factor Rev. 15:61–76. 2004. View Article : Google Scholar : PubMed/NCBI
35	Mittal SK and Roche PA: Suppression of antigen presentation by IL-10. Curr Opin Immunol. 34:22–27. 2015. View Article : Google Scholar : PubMed/NCBI
36	Han L, Yang J, Wang X, Li D, Lv L and Li B: Th17 cells in autoimmune diseases. Front Med. 9:10–19. 2015. View Article : Google Scholar : PubMed/NCBI
37	Housseau F, Wu S, Wick EC, Fan H, Wu X, Llosa NJ, Smith KN, Tam A, Ganguly S, Wanyiri JW, et al: Redundant innate and adaptive sources of IL17 production drive colon tumorigenesis. Cancer Res. 76:2115–2124. 2016. View Article : Google Scholar : PubMed/NCBI
38	Patil RS, Shah SU, Shrikhande SV, Goel M, Dikshit RP and Chiplunkar SV: IL17 producing γδ T cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int J Cancer. 139:869–881. 2016. View Article : Google Scholar : PubMed/NCBI
39	Benevides L, da Fonseca DM, Donate PB, Tiezzi DG, De Carvalho DD, de Andrade JM, Martins GA and Silva JS: IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment. Cancer Res. 75:3788–3799. 2015. View Article : Google Scholar : PubMed/NCBI
40	Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H and Lotze MT: Interleukin-17 promotes angiogenesis and tumor growth. Blood. 101:2620–2627. 2003. View Article : Google Scholar : PubMed/NCBI
41	Lee EJ, Park HJ, Lee IJ, Kim WW, Ha SJ, Suh YG and Seong J: Inhibition of IL-17A suppresses enhanced-tumor growth in low dose pre-irradiated tumor beds. PLoS One. 9:e1064232014. View Article : Google Scholar : PubMed/NCBI
42	Ju X, Ijaz T, Sun H, Ray S, Lejeune W, Lee C, Recinos A III, Guo DC, Milewicz DM, Tilton RG and Brasier AR: Interleukin-6-signal transducer and activator of transcription-3 signaling mediates aortic dissections induced by angiotensin II via the T-helper lymphocyte 17-interleukin 17 axis in C57BL/6 mice. Arterioscler Thromb Vasc Biol. 33:1612–1621. 2013. View Article : Google Scholar : PubMed/NCBI
43	Kumar P: Natarajan K and Shanmugam N: High glucose driven expression of pro-inflammatory cytokine and chemokine genes in lymphocytes: Molecular mechanisms of IL-17 family gene expression. Cell Signal. 26:528–539. 2014. View Article : Google Scholar : PubMed/NCBI
44	Chen XW and Zhou SF: Inflammation, cytokines, the IL-17/IL-6/STAT3/NF-κB axis, and tumorigenesis. Drug Des Devel Ther. 9:2941–2946. 2015.PubMed/NCBI
45	Hu Z, Luo D, Wang D, Ma L, Zhao Y and Li L: IL-17 activates the IL-6/STAT3 signal pathway in the proliferation of hepatitis B virus-related hepatocellular carcinoma. Cell Physiol Biochem. 43:2379–2390. 2017. View Article : Google Scholar : PubMed/NCBI
46	Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP and Zheng L: Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 50:980–989. 2009. View Article : Google Scholar : PubMed/NCBI
47	Du JW, Xu KY, Fang LY and Qi XL: Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer. Mol Med Rep. 6:1099–1102. 2012. View Article : Google Scholar : PubMed/NCBI
48	Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M and Cheroutre H: Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 317:256–260. 2007. View Article : Google Scholar : PubMed/NCBI
49	Wu C, Wang S, Wang F, Chen Q, Peng S, Zhang Y, Qian J, Jin J and Xu H: Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol. 158:199–204. 2009. View Article : Google Scholar : PubMed/NCBI
50	Waters JP, Pober JS and Bradley JR: Tumour necrosis factor and cancer. J Pathol. 230:241–248. 2013. View Article : Google Scholar : PubMed/NCBI
51	Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, Copland M, Jørgensen HG and Holyoake TL: Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood. 122:3335–3339. 2013. View Article : Google Scholar : PubMed/NCBI
52	Sanchez-Correa B, Bergua JM, Campos C, Gayoso I, Arcos MJ, Bañas H, Morgado S, Casado JG, Solana R and Tarazona R: Cytokine profiles in acute myeloid leukemia patients at diagnosis: Survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine. 61:885–891. 2013. View Article : Google Scholar : PubMed/NCBI
53	Potapnev MP, Petyovka NV, Belevtsev MV, Savitskiy VP and Migal NV: Plasma level of tumor necrosis factor-alpha (TNF-alpha) correlates with leukocytosis and biological features of leukemic cells, but not treatment response of children with acute lymphoblastic leukemia. Leuk Lymphoma. 44:1077–1079. 2003. View Article : Google Scholar : PubMed/NCBI
54	Foa R, Massaia M, Cardona S, Tos AG, Bianchi A, Attisano C, Guarini A, di Celle PF and Fierro MT: Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: A possible regulatory role of TNF in the progression of the disease. Blood. 76:393–400. 1990.PubMed/NCBI
55	Lech-Maranda E, Grzybowska-Izydorczyk O, Wyka K, Mlynarski W, Borowiec M, Antosik K, Cebula-Obrzut B, Makuch-Lasica H, Nowak G, Klimkiewicz-Wojciechowska G, et al: Serum tumor necrosis factor-alpha and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status. Arch Immunol Ther Exp (Warsz). 60:477–486. 2012. View Article : Google Scholar : PubMed/NCBI
56	Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, et al: The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood. 100:1215–1219. 2002.PubMed/NCBI
57	Kupsa T, Vasatova M, Karesova I, Zak P and Horacek JM: Baseline serum levels of multiple cytokines and adhesion molecules in patients with acute myeloid leukemia: Results of a pivotal trial. Exp Oncol. 36:252–257. 2014.PubMed/NCBI
58	Fung FY, Li M, Breunis H, Timilshina N, Minden MD and Alibhai SM: Correlation between cytokine levels and changes in fatigue and quality of life in patients with acute myeloid leukemia. Leuk Res. 37:274–279. 2013. View Article : Google Scholar : PubMed/NCBI
59	Hess P, Pihan G, Sawyers CL, Flavell RA and Davis RJ: Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet. 32:201–205. 2002. View Article : Google Scholar : PubMed/NCBI
60	Tsai HJ, Kobayashi S, Izawa K, Ishida T, Watanabe T, Umezawa K, Lin SF and Tojo A: Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment. Cancer Sci. 102:2014–2021. 2011. View Article : Google Scholar : PubMed/NCBI
61	Volk A, Li J, Xin J, You D, Zhang J, Liu X, Xiao Y, Breslin P, Li Z, Wei W, et al: Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML. J Exp Med. 211:1093–1108. 2014. View Article : Google Scholar : PubMed/NCBI